Hikma Pharmaceuticals (LON:HIK) was downgraded by analysts at Jefferies Group to an “underperform” rating in a research report issued to clients and investors on Wednesday, January 10th. They currently have a GBX 895 ($12.57) price objective on the stock, down from their prior price objective of GBX 1,074 ($15.08). Jefferies Group’s target price would suggest a potential downside of 6.28% from the stock’s previous close.
Several other equities analysts have also recently commented on the company. Numis Securities reaffirmed a “buy” rating and issued a GBX 1,300 ($18.26) price target on shares of Hikma Pharmaceuticals in a report on Wednesday, December 20th. JPMorgan Chase & Co. lowered their price objective on Hikma Pharmaceuticals from GBX 1,500 ($21.06) to GBX 1,250 ($17.55) and set a “neutral” rating on the stock in a research note on Friday, October 6th. Morgan Stanley reiterated an “equal weight” rating and issued a GBX 1,100 ($15.45) price objective on shares of Hikma Pharmaceuticals in a research note on Friday, December 1st. Peel Hunt reiterated a “hold” rating and issued a GBX 1,390 ($19.52) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 15th. Finally, Stifel Nicolaus lowered their price objective on Hikma Pharmaceuticals from GBX 1,320 ($18.54) to GBX 1,000 ($14.04) and set a “hold” rating on the stock in a research note on Thursday, November 9th. Two analysts have rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,171 ($16.44).
Hikma Pharmaceuticals (LON:HIK) traded down GBX 12 ($0.17) during trading on Wednesday, reaching GBX 955 ($13.41). The company’s stock had a trading volume of 364,685 shares, compared to its average volume of 446,101. The firm has a market cap of $2,290.00 and a PE ratio of 1,948.98. Hikma Pharmaceuticals has a 12-month low of GBX 906.50 ($12.73) and a 12-month high of GBX 2,346 ($32.94).
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/01/jefferies-group-lowers-hikma-pharmaceuticals-hik-to-underperform.html.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.